Lablab bean
Lablab purpureus. FRIL lectin, studied in the literature for anti-influenza activity at viral attachment.
Feed program
We are converting published, ingredient-level evidence into a standardized feed additive that can be manufactured, quality-specified, and evaluated under controlled conditions. The route is ordinary commercial poultry feed. The research objective is host-level nutritional support in flocks that live with avian-influenza pressure. Biological performance has not been established. We are looking for mills, labs, and producers to help build the next stages.
Highly pathogenic avian influenza (HPAI) has been the most extensive avian-influenza event in modern U.S. poultry production. Federal reporting documents outbreak activity across all fifty states, with cumulative losses exceeding 179 million birds since February 2022 and continuing commercial detections through 2026.
The existing control framework rests on four pillars: farm biosecurity, surveillance and rapid outbreak response, depopulation of affected and exposed flocks, and continuing development of vaccination and therapeutic options. Each is essential. Considered together, however, they are directed principally at preventing viral introduction, detecting infection, containing transmission, or eliminating affected flocks after detection.
Two constraints are documented in the federal record. USDA's Agricultural Research Service has stated that vaccination for HPAI is not currently used in U.S. commercial poultry because of trade implications. Federal regulation prohibits extra-label use of adamantanes and neuraminidase inhibitors in chickens, turkeys, and ducks, and USDA APHIS states that there is no treatment for HPAI. The U.S. Secretary of Agriculture has described the policy position directly: "There is no silver bullet to eradicating avian flu."
The gap under study
The framework contains comparatively little in the way of a routinely administered, flock-level nutritional option developed specifically to support the bird's own biological resilience before exposure occurs. That is the gap we are investigating. It is a complementary layer, not a replacement for biosecurity, surveillance, vaccination policy, or regulatory outbreak response.
Phytogenic feed additives are already well established in poultry nutrition, and commercial feed systems routinely incorporate plant-derived functional ingredients. We apply that established delivery platform to a disease-resilience research objective rather than to the production-performance objectives around which most commercial phytogenic products are positioned.
Four components were selected on the basis of published peer-reviewed literature describing antiviral, immunomodulatory, antioxidant, or host-defense properties, together with their suitability for feed delivery and the feasibility of sourcing and standardizing them at commercial scale. Full citations are on the science page.
Lablab purpureus. FRIL lectin, studied in the literature for anti-influenza activity at viral attachment.
Camellia sinensis. EGCG and ECG. Published poultry work has evaluated feed-administered green-tea material.
Allium sativum. Organosulfur compounds including allicin, described in connection with antiviral and immunomodulatory activity.
Zingiber officinale. Gingerols and related compounds described in connection with antioxidant activity.
Citations and the boundary between published findings and this untested formulation are on the science page. The four components are designed as a system. Whether the combined formulation produces the intended effects remains an open question.
Commercial poultry consume formulated feed daily. A properly developed additive can therefore be administered flock-wide through infrastructure that already exists, without individual bird handling and without farm-level infrastructure change. That has three consequences for how we work:
This is not an ingredient-discovery project. The work is the translational sequence that determines whether published ingredient-level evidence can become a product a mill can run:
| Work stream | Content |
|---|---|
| Formulation | Ingredient specifications, candidate inclusion ranges, carrier optimization, feed-matrix compatibility, palatability and tolerance. |
| Analytical | Marker-compound methods, bioactive retention through processing and storage, stability programs, mixing uniformity. |
| Validation | Safety and tolerance endpoints, immune- and antioxidant-response endpoints, and disease-relevant evaluation conducted only in appropriately qualified facilities. |
| Regulatory | Ingredient-status review, FDA Center for Veterinary Medicine requirements, AAFCO definitions and state feed-control provisions, and a lawful claim set supported by generated data. |
| Manufacturing & quality | Supplier qualification, certificates of analysis, incoming-lot specifications, pilot batches, batch-release controls, quality assurance. |
Current stage, completed work, and what has deliberately not yet been established are on the progress page and updated as milestones are reached.
We draw on specialized U.S. capability at each stage: analytical laboratories, university poultry-research units and contract research organizations, regulatory and quality professionals, ingredient suppliers, contract manufacturers, feed mills, and commercial poultry producers. If that is you, write — including at stages earlier than field evaluation. See Work with us.